Peptonic Medical AB (publ) (the "Company") announces that the Company has terminated its agreement with Mangold Fondförvaltning AB regarding the assignment as liquidity provider.
The purpose of the liquidity provider arrangement has been to promote liquidity in the Company's share, reduce volatility and facilitate trading. The Company assesses that the current trading and liquidity in the share are satisfactory and that the benefit of a liquidity provider is therefore limited.
The liquidity provider arrangement ceased after the close of trading on 23 February 2026.
For more information contact:
Anna Linton, VD Peptonic Medical AB
Email: anna.linton@peptonicmedical.se
Phone: +46 70-244 92 07
About Peptonic Medical AB Peptonic Medical AB (publ) is a pioneering Swedish medtech company specializing in the development and sale of clinically proven self-care products for women's intimate health. Through its brands VagiVital and Vernivia, the Company offers a broad over-the-counter portfolio of effective and gentle products designed to help women understand, treat, and prevent common medical conditions in the intimate area. Peptonic's growth strategy centers on geographic expansion, particularly in the U.S. and Europe, while continually enhancing its product portfolio through in-house development and strategic acquisitions.
The Company is headquartered in Stockholm, Sweden, and operates the subsidiaries, Peptonic Medical Inc. and Common Sense Marketing Inc., in the U.S. Peptonic Medical was founded in 2009 and has been listed on the Spotlight Stock Market since 2014.